TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7769060

Group type: EXPERIMENTAL
Intervention: Surgical ligation
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Radiological embolization
Number of subjects: 95

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 95
Study: 2189972

Group type: EXPERIMENTAL
Intervention: Composite resins
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amalgam (dispersed phase alloy)
Number of subjects: 0
Study: 374444

Group type: EXPERIMENTAL
Intervention: Group A (ZEEP ventilation)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Group B (PEEP 10 cm H2O with CPAP)
Number of subjects: 30
Study: 31314108

Group type: EXPERIMENTAL
Intervention: darunavir/ritonavir 800/100 mg monotherapy
Number of subjects: 77
Study: 28625256

Group type: EXPERIMENTAL
Intervention: Terlipressin (0.01-0.04 U/min)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Norepinephrine (> 1 μg/min)
Number of subjects: 57
Study: 25736441

Group type: EXPERIMENTAL
Intervention: Dose change-based method for calculating individual patient time in therapeutic range (iTTR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Rosendaal method for calculating iTTR
Number of subjects: 0
Study: 23573843

Group type: EXPERIMENTAL
Intervention: Jaw-thrust manoeuvre
Number of subjects: 82
Study: 22010917

Group type: EXPERIMENTAL
Intervention: Low-poverty housing vouchers with counseling on moving
Number of subjects: 4498

Group type: EXPERIMENTAL
Intervention: Traditional housing vouchers without counseling
Number of subjects: 4498

Group type: COMPARATOR
Intervention: Control group (no vouchers)
Number of subjects: 4498
Study: 19327603

Group type: EXPERIMENTAL
Intervention: Urapidil (12.5 mg, ic)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study: 16703538

Group type: EXPERIMENTAL
Intervention: Zyoptix wavefront-guided PRK
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard PRK (PlanoScan)
Number of subjects: 56
Study: 14677617

Group type: EXPERIMENTAL
Intervention: Glass ionomer cement
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Polyacid-modified resin cement
Number of subjects: 27

Group type: COMPARATOR
Intervention: Non-fluoride releasing zinc phosphate cement
Number of subjects: 27
Study: 10611189

Group type: EXPERIMENTAL
Intervention: Melatonin 6 mg orally every day at 1700 h for 1 month
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Melatonin 6 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 6
Study: 9189814

Group type: EXPERIMENTAL
Intervention: Elastase (10800 EL. U. P.O. per day) with an antiplatelet drug
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (only antiplatelet drug)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Elastase (10800 EL. U. P.O. per day) with an antiplatelet drug (when autogenous saphenous veins were used)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (only antiplatelet drug, when autogenous saphenous veins were used)
Number of subjects: 104
Study: 1487662

Group type: EXPERIMENTAL
Intervention: Calcium sodium alginate fibre (Kaltostat)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Petrolatum gauze impregnated with bismuth tribromophenate (Xeroform)
Number of subjects: 40
Study: 3887547

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice daily)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Antacid (Novaluzid; 10 ml seven times daily, with a neutralizing capacity of 600 mmol H+)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Whole groups (combined results)
Number of subjects: 119
Study: 31421138

Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (RT-CGM)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Blinded continuous glucose monitoring (Blinded-CGM)
Number of subjects: 20
Study: 29651052

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII) therapy
Number of subjects: 102

Group type: COMPARATOR
Intervention: Insulin glargine based multiple injections (MDI) therapy
Number of subjects: 102
Study: 26089214

Group type: EXPERIMENTAL
Intervention: Aspheric toric intraocular lens (IOL) implantation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Limbal relaxing incisions (LRI)
Number of subjects: 60
Study: 25172269

Group type: EXPERIMENTAL
Intervention: Restrictive baseline symptom severity thresholds
Number of subjects: 0
Study: 22732135

Group type: EXPERIMENTAL
Intervention: Self-monitoring of mood, stress, and daily activities for 2 to 4 weeks.
Number of subjects: 114

Group type: COMPARATOR
Intervention: Attention comparison group (only daily activities monitored) for 2 to 4 weeks.
Number of subjects: 114
Study: 20032123

Group type: COMPARATOR
Intervention: Concomitant chemoradiotherapy (CT/RT) alone (arm A: two cycles of cisplatin 20 mg/m(2), days 1-4, plus 5‐fluorouracil 800 mg/m(2)/day 96 h continuous infusion during weeks 1 and 6 of radiotherapy)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Induction docetaxel, cisplatin and 5‐fluorouracil (TPF) followed by concomitant chemoradiotherapy (arm B: three cycles of TPF: docetaxel 75 mg/m(2) and cisplatin 80 mg/m(2), day 1, and 5‐fluorouracil 800 mg/m(2)/day 96 h continuous infusion, every 3 weeks)
Number of subjects: 101
Study: 18614721

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 15

Group type: COMPARATOR
Intervention: Niacin
Number of subjects: 15

Group type: COMPARATOR
Intervention: Niacin + Exercise
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (high-fat meal only)
Number of subjects: 15
Study: 15824925

Group type: EXPERIMENTAL
Intervention: Revascularisation
Number of subjects: 384

Group type: COMPARATOR
Intervention: No revascularisation (Control)
Number of subjects: 384
Study: 12456227

Group type: EXPERIMENTAL
Intervention: BMI of 30 or greater
Number of subjects: 21414

Group type: EXPERIMENTAL
Intervention: Each unit increase of BMI
Number of subjects: 21414

Group type: EXPERIMENTAL
Intervention: Adjustment for hypertension, diabetes mellitus, and hypercholesterolemia
Number of subjects: 21414
Study: 10834024

Group type: EXPERIMENTAL
Intervention: Calcium and vitamins (30,000 IU vitamin A, 1 g vitamin C, 70 mg vitamin E, 2 g calcium)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Calcium and vitamins (after 6 months discontinuation)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (after 6 months discontinuation)
Number of subjects: 90
Study: 8861437

Group type: EXPERIMENTAL
Intervention: Gelseal Vascutek graft immersed for 15 min in a solution containing 1 mg/ml rifampicin (group A)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Untreated Gelseal Vascutek graft (group B)
Number of subjects: 600
Study: 1403864

Group type: EXPERIMENTAL
Intervention: Fluid wax
Number of subjects: 30

Group type: COMPARATOR
Intervention: Light-body polysulfide rubber
Number of subjects: 30
Study: 6147067

Group type: COMPARATOR
Intervention: Basal therapy (B) with monthly appointments
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Therapist-directed prolonged exposure in vivo (PE)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Relaxation therapy (R)
Number of subjects: 23
Study: 30601319

Group type: EXPERIMENTAL
Intervention: ACEIs-combined (n = 369)
Number of subjects: 470
Study: 27486681

Group type: EXPERIMENTAL
Intervention: Tübingen exercise therapy approach (THüKo)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo ultrasound
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 210
Study: 25290345

Group type: EXPERIMENTAL
Intervention: Autonomy (free timing of break)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard conditions (fixed timing of break)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Increased autonomy
Number of subjects: 60
Study: 23379535

Group type: EXPERIMENTAL
Intervention: HEIA intervention
Number of subjects: 700
Study: 21958650

Group type: EXPERIMENTAL
Intervention: Delayed reaction time task mimicking encoding, rehearsal, and recall stages of VSTM
Number of subjects: 0
Study: 18840133

Group type: EXPERIMENTAL
Intervention: Immunohistochemical analysis using Ber‐EP4 antibody
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Immunohistochemical analysis using AE1/AE3 antibody
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Immunohistochemical analysis using CAM 5.2 antibody
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Presence of nodal micrometastases
Number of subjects: 20
Study: 16504324

Group type: EXPERIMENTAL
Intervention: L. plantarum MF1298
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: L. pentosus DC13
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: L. plantarum MF1298 (as sausage)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: L. pentosus DC13 (as sausage)
Number of subjects: 17
Study: 12771612

Group type: EXPERIMENTAL
Intervention: Helium/oxygen mixture
Number of subjects: 13

Group type: COMPARATOR
Intervention: Air/oxygen mixture
Number of subjects: 13
Study: 11062570

Group type: EXPERIMENTAL
Intervention: Topical lignocaine‐prilocaine anaesthetic cream
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 9258888

Group type: EXPERIMENTAL
Intervention: 15 ml/kg of lactated ringer intravenously as prehydration
Number of subjects: 44

Group type: COMPARATOR
Intervention: Trendelenbourg position to 30 degrees for 2 minutes and legs wrapped with elastic Esmarch bandage
Number of subjects: 44
Study: 8488820

Group type: EXPERIMENTAL
Intervention: Cuprophan membrane (CU)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hemophan membrane (HE)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Polyamide membrane (PA)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Polyamide membrane, large dialyzer area, low Qb for 4 hours
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Polyamide dialysis at low Qb for 4 hours
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Polyamide dialysis at high Qb for 2 hours
Number of subjects: 20
Study: 3032640

Group type: EXPERIMENTAL
Intervention: Gaviscon
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2685045

Group type: EXPERIMENTAL
Intervention: Tailored psychological treatment of insomnia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untailored treatment (stimulus control therapy)
Number of subjects: 0
Study: 30053853

Group type: EXPERIMENTAL
Intervention: Midwifery group practice (MGP) care
Number of subjects: 115

Group type: COMPARATOR
Intervention: Standard hospital maternity care (SC)
Number of subjects: 115
Study: 28497700

Group type: EXPERIMENTAL
Intervention: Focused intention meditation by biofield practitioners
Number of subjects: 286

Group type: COMPARATOR
Intervention: Control group (blinded operator selected water samples)
Number of subjects: 286
Study: 25572279

Group type: EXPERIMENTAL
Intervention: Calmare® treatment (up to 10 sessions)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham treatment (non-therapeutic threshold)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Calmare® treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 30
Study: 23363640

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Graded Exercise Therapy (GET)
Number of subjects: 585

Group type: COMPARATOR
Intervention: Adaptive Pacing Therapy (APT)
Number of subjects: 585

Group type: COMPARATOR
Intervention: Specialist Medical Care (SMC)
Number of subjects: 585
Study: 21490695

Group type: EXPERIMENTAL
Intervention: Vitamin C (2 g) and E (800 IU)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 18465470

Group type: EXPERIMENTAL
Intervention: Cold pressor stress (CPS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control procedure
Number of subjects: 80
Study: 16183188

Group type: EXPERIMENTAL
Intervention: GnRH antagonist (GnRH‐ant)
Number of subjects: 60

Group type: COMPARATOR
Intervention: GnRH agonist (GnRH‐a)
Number of subjects: 60
Study: 15169798

Group type: EXPERIMENTAL
Intervention: Four vaccinations with fowlpox‐PSA (rF‐PSA)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Three rF‐PSA vaccines followed by one vaccinia‐PSA (rV‐PSA) vaccine
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: One rV‐PSA vaccine followed by three rF‐PSA vaccines
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Overall treatment with poxviruses expressing PSA
Number of subjects: 64
Study: 11719300

Group type: EXPERIMENTAL
Intervention: 20-min exercise session
Number of subjects: 29

Group type: COMPARATOR
Intervention: Video control condition (information about exercise and cholesterol)
Number of subjects: 29
Study: 9233107

Group type: EXPERIMENTAL
Intervention: ParaGraph
Number of subjects: 40

Group type: COMPARATOR
Intervention: Timed-dose
Number of subjects: 40
Study: 8425810

Group type: EXPERIMENTAL
Intervention: Topical paromomycin treatment
Number of subjects: 91

Group type: COMPARATOR
Intervention: Untreated (control group)
Number of subjects: 91
Study: 3306289

Group type: EXPERIMENTAL
Intervention: Org OD 14
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 30356343

Group type: EXPERIMENTAL
Intervention: Paracervical injection of 0.25% bupivacaine with epinephrine
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo (20 mL normal saline)
Number of subjects: 132
Study: 27158956

Group type: EXPERIMENTAL
Intervention: SHIELD program (team-based health promotion program)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 24731118

Group type: EXPERIMENTAL
Intervention: e‐TOKE program
Number of subjects: 317

Group type: COMPARATOR
Intervention: assessment‐only control
Number of subjects: 317
Study: 21951314

Group type: EXPERIMENTAL
Intervention: SB‐705498 (TRPV1 blocker) administered via nasal lavage 2 minutes before each allergen challenge.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 20162717

Group type: EXPERIMENTAL
Intervention: Morning arm (8:00-10:00 AM)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Evening arm (6:00-8:00 PM)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Other radiation-induced toxicity in morning arm
Number of subjects: 229

Group type: COMPARATOR
Intervention: Other radiation-induced toxicity in evening arm
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Response to radiation in morning arm
Number of subjects: 229

Group type: COMPARATOR
Intervention: Response to radiation in evening arm
Number of subjects: 229
Study: 19253509

Group type: EXPERIMENTAL
Intervention: nsNIMV
Number of subjects: 48

Group type: COMPARATOR
Intervention: NCPAP
Number of subjects: 48
Study: 16192763

Group type: EXPERIMENTAL
Intervention: 15 mg/kg acetaminophen
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 22.5 mg/kg acetaminophen
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 30 mg/kg acetaminophen
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Acetaminophen (all doses)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Cold pressor test
Number of subjects: 13
Study: 12736839

Group type: EXPERIMENTAL
Intervention: Training for 6 months, three times a week, with running at 85‐120% of the lactate anaerobic threshold (LT)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Training for 6 months
Number of subjects: 18

Group type: COMPARATOR
Intervention: Untrained
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Prepubertal twins
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Pubertal twins
Number of subjects: 18
Study: 11321284

Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 291

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study: 9288701

Group type: EXPERIMENTAL
Intervention: Estraderm MX 50 (0.05 mg estradiol per day)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 7506163

Group type: EXPERIMENTAL
Intervention: Nimesulide (100mg twice daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Naproxen (250mg twice daily)
Number of subjects: 60
Study: 3828183

Group type: EXPERIMENTAL
Intervention: 3% 2‐chloroprocaine 23 ml administered in head-up position
Number of subjects: 50

Group type: COMPARATOR
Intervention: 3% 2‐chloroprocaine 23 ml administered in supine position
Number of subjects: 50
Study: 29885026

Group type: EXPERIMENTAL
Intervention: Telephone-delivered exercise therapy
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Telephone-delivered care
Number of subjects: 8
Study: 28989140

Group type: EXPERIMENTAL
Intervention: Superelastic NiTi arch wires
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Heat-activated NiTi arch wires
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study: 26280247

Group type: EXPERIMENTAL
Intervention: Polypill strategy (containing a statin, antiplatelet agent, and two blood-pressure-lowering medications)
Number of subjects: 623

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Polypill strategy
Number of subjects: 623
Study: 24074738

Group type: EXPERIMENTAL
Intervention: D-aspartic acid (D-ASP) supplementation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 21823422

Group type: EXPERIMENTAL
Intervention: Tangzu Yuyang Ointment (TYO) plus Standard Wound Therapy (SWT)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Standard Wound Therapy (SWT)
Number of subjects: 57
Study: 19923205

Group type: EXPERIMENTAL
Intervention: Early feedback of a public report card on baseline performance (January 2004)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Delayed feedback of a public report card on baseline performance (September 2005)
Number of subjects: 86
Study: 17368881

Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) supplementation (2.2 g daily for 8 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14687104

Group type: EXPERIMENTAL
Intervention: New drug administration system
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional methods
Number of subjects: 30
Study: 11150936

Group type: EXPERIMENTAL
Intervention: Baseline assessment
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Follow-up assessment
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 45
Study: 9745973

Group type: EXPERIMENTAL
Intervention: Midodrine hydrochloride, dosage and duration not specified
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7818196

Group type: EXPERIMENTAL
Intervention: Propacetamol (2 g) combined with nalbuphine hydrochloride (10 mg)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Nalbuphine hydrochloride (20 mg)
Number of subjects: 152
Study: 2898717

Group type: EXPERIMENTAL
Intervention: 25 micrograms of SMS
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 50 micrograms of SMS
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 100 micrograms of SMS
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31980022

Group type: EXPERIMENTAL
Intervention: Flaxseed powder (30 g/day) plus lifestyle modification
Number of subjects: 41

Group type: COMPARATOR
Intervention: Lifestyle modification
Number of subjects: 41
Study: 30895611

Group type: COMPARATOR
Intervention: Oral metronidazole (400 mg, three times per day for 7 days)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combined vaginal tablet (nystatin 100,000 U, diiodohydroxyquin 100 mg, benzalkonium chloride 7 mg, once daily for 7 days)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Oral metronidazole
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combined vaginal tablet
Number of subjects: 90
Study: 28554914

Group type: EXPERIMENTAL
Intervention: Retrospective + momentary assessment (Edinburgh Postnatal Depression Scale + five momentary and two contextual questions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Retrospective assessment (Edinburgh Postnatal Depression Scale only)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both assessment strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Momentary assessments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: App usage
Number of subjects: 0
Study: 25602854

Group type: EXPERIMENTAL
Intervention: CMR
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham CMR
Number of subjects: 60
Study: 23128968

Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg twice a day plus aspirin 100 mg a day
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo plus aspirin 100 mg a day
Number of subjects: 203
Study: 21551248

Group type: EXPERIMENTAL
Intervention: Lung age‐based motivational strategy
Number of subjects: 67

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Lung age interaction with intervention strategy
Number of subjects: 67
Study: 19388074

Group type: EXPERIMENTAL
Intervention: Targeted care bundle consisting of medication counseling/reconciliation by a clinical pharmacist, condition specific education/enhanced discharge planning by a care coordinator, and phone follow-up.
Number of subjects: 41

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Targeted care bundle.
Number of subjects: 41
Study: 16687453

Group type: EXPERIMENTAL
Intervention: Group C (audiovisual presentation)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Group A (verbal presentation)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Group B (diagrams with verbal presentation)
Number of subjects: 90
Study: 15282063

Group type: EXPERIMENTAL
Intervention: Rilmenidine (1 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11224782

Group type: EXPERIMENTAL
Intervention: Open surgical tracheostomy
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Endoscopically guided percutaneous dilational tracheotomy
Number of subjects: 164
Study: 9402818

Group type: EXPERIMENTAL
Intervention: High-speed, high-resolution thermography
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control subjects (normal subjects)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (normal blinking vs keeping eyes open after closing)
Number of subjects: 20
Study: 8527004

Group type: EXPERIMENTAL
Intervention: Auditory stimuli (tones at 70 dB SPL, oddball paradigm with 1.5K vs. 1K tones)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Visual stimuli (2.3 cpd sinusoidal grating patterns, oddball paradigm with oblique vs. vertical orientation)
Number of subjects: 50